TG Therapeutics, Inc. reported a modest Q3 beat and raised the full-year net sales guidance range for Briumvi by $7.5 million ...

It's been a good week for TG Therapeutics, Inc. ( NASDAQ:TGTX ) shareholders, because the company has just released ...

TG Therapeutics (NASDAQ:TGTX – Free Report) had its target price increased by HC Wainwright from $49.00 to $55.00 in a report ...

Greetings and welcome to the TG Therapeutics third quarter conference call and webcast. At this time, all participants are in listen-only mode. If anyone should require operator assistance ...

On Friday, TG Therapeutics Inc common stock (TGTX) stock saw a modest uptick, ending the day at $28.81 which represents a slight increase of $0.91 or 3.26% from the prior close of $27.9. The stock ...

NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the third quarter of 2024, along with recent ...

TG Therapeutics ( (TGTX)) has released its Q3 earnings. Here is a breakdown of the information TG Therapeutics presented to its investors. TG Therapeutics is a biopharmaceutical company focused on ...

TG Therapeutics develops treatments for B-cell diseases, with a primary focus on multiple sclerosis. Its lead product, Briumvi, serves as the cornerstone of its commercial success. Briumvi ...

Analyst Mayank Mamtani of B.Riley Financial reiterated a Buy rating on TG Therapeutics (TGTX – Research Report), retaining the price target of $38.00. Mayank Mamtani’s rating is based on TG ...

Greetings and welcome to the TG Therapeutics third quarter conference call and webcast. At this time, all participants are in listen-only mode. If anyone should require operator assistance, please ...